332 related articles for article (PubMed ID: 26391357)
1. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
[TBL] [Abstract][Full Text] [Related]
2. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
3. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
4. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
6. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
7. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Sountoulides P; Roehrborn CG; Mirone V; Schips L
Int Urol Nephrol; 2014 Apr; 46(4):695-701. PubMed ID: 24136187
[TBL] [Abstract][Full Text] [Related]
8. Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Koh JS; Cho KJ; Kim HS; Kim JC
Int J Clin Pract; 2014 Feb; 68(2):197-202. PubMed ID: 24372906
[TBL] [Abstract][Full Text] [Related]
9. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
10. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
11. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
12. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
14. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
[TBL] [Abstract][Full Text] [Related]
16. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.
Roehrborn CG; Nuckolls JG; Wei JT; Steers W;
BJU Int; 2007 Oct; 100(4):813-9. PubMed ID: 17822462
[TBL] [Abstract][Full Text] [Related]
17. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
18. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
19. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?
Fusco F; Arcaniolo D; Creta M; Piccinocchi G; Arpino G; Laringe M; Piccinocchi R; Longo N; Verze P; Mangiapia F; Imperatore V; Mirone V
World J Urol; 2015 May; 33(5):685-9. PubMed ID: 25491675
[TBL] [Abstract][Full Text] [Related]
20. A review of combination therapy in patients with benign prostatic hyperplasia.
McVary KT
Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
